U.S. Department of Health & Human Services
Open Funding Opportunities
| NOFO # | NOFO Title | Research Focus Area | Earliest Submission Date | Expiration Date | Posted Date Sort ascending |
|---|---|---|---|---|---|
| PAR-25-328 Show Summary |
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Mon, 03/10/2025 | Tue, 08/12/2025 | Fri, 01/03/2025 |
|
The purpose of this funding opportunity is to support research to advance the development of safe and effective medications for the treatment of Substance Use Disorders (SUD). It includes preclinical and/or clinical research projects, from lead optimization all the way Phase I, Phase II, and Phase III clinical trials. The goal is to fund studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. |
|||||
| PAR-25-329 Show Summary |
Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Mon, 03/10/2025 | Tue, 08/12/2025 | Fri, 01/03/2025 |
|
The National Institute on Drug Abuse (NIDA) seeks research for the discovery and development of medications to prevent and treat substance use disorders (SUDs) and overdose. The UG3/UH3 Phased Innovation Awards Cooperative Agreement funding mechanism involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to or to FDA approval. The compounds to be evaluated can be small molecules or biologic and may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications. Through this funding opportunity, NIDA seeks to fast-track the discovery and development of medications to prevent and treat SUDs and overdose and to advance them in the FDA's pathway. |
|||||
| NOT-DA-23-009 | Notice of Special Interest (NOSI): HEAL Initiative: Grand Opportunity in Medications Development for Substance-Use Disorders | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Thu, 10/27/2022 | Tue, 09/02/2025 | Thu, 09/29/2022 |
|
no summary
|
|||||
| NOT-DA-23-010 | Notice of Special Interest (NOSI): HEAL Initiative: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose | Novel Therapeutic Options for Opioid Use Disorder and Overdose | Thu, 10/27/2022 | Tue, 09/02/2025 | Wed, 09/28/2022 |
|
no summary
|
|||||